Purchase this article with an account.
F.A. Bucci, Jr; A Comparison of Conjunctival and Eyelid Cultures in Phaco Patients Using Gatifloxacin and Moxifloxacin Preoperatively . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4017.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose:To compare the impact of topical gatifloxacin and moxifloxacin on preop conjunctival and eyelid cultures in patients undergoing phacoemulsifcation. Methods:: Group I contained 100 patients randomized to receive either gatifloxacin (n=50) or moxifloxacin (n=50) 4 x day for 2 days preop, and 1 drop in the AM before surgery. Group II contained 120 patients randomized to receive either gatifloxacin (n=60) or moxifloxacin (n=60) 4 x day for 2 days preop, and 1 drop in the AM before surgery + 1 drop every 10 min x 4 in the hour prior to surgery. All conjunctival and eyelid cultures (BBL Culture Swab Plus) were obtained in a masked fashion prior to using povidone–iodine. Results: The mean number of colony–forming units in Group I (9 preop drops) was (gatifloxacin–conj) 59.9 + 165.6, (moxifloxacin–conj) 57.0 + 214.7, (gatifloxacin–eyelid) 198.1 + 330.1, and (moxifloxacin–eyelid) 168.3 + 379.0. The mean number of colony–forming units in Group II (13 preop drops) was (gatifloxacin–conj) 76.7 + 327.7, (moxifloxacin–conj) 92.0 + 486.1, (gatifloxacin–eyelid) 556.8 + 1,029.3, (moxifloxacin–eyelid) 596.5 + 1,013.5. No statistically significant differences were detected between the gatifloxacin and moxifloxacin eyes for either group on the conjunctiva or eyelids. There were no significant differences in the percent of specimens containing staph species – gatifloxacin (I + II) conj 55%/eyelid 79% and moxifloxacin (I + II) conj 47%/eyelid 83%. There were also no significant difference in the percent of other types of species detected such as strep, p. acnes, bacillus, corynebacterium, and gram negatives. Conclusions: This in vivo study revealed no significant differences in the efficacy to reduce the bacterial load on the eyelids and conjunctiva prior to phacoemulsification when comparing the new fourth–generation fluoroquinolones gatifloxacin and moxifloxacin.
This PDF is available to Subscribers Only